DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Piper Jaffray Companies raised their Q4 2018 EPS estimates for DexCom in a research note issued to investors on Tuesday, November 6th. Piper Jaffray Companies analyst J. Mckim now forecasts that the medical device company will earn $0.09 per share for the quarter, up from their prior estimate of $0.05. Piper Jaffray Companies has a “Overweight” rating and a $157.00 price target on the stock. Piper Jaffray Companies also issued estimates for DexCom’s Q4 2019 earnings at $0.20 EPS and FY2020 earnings at $0.56 EPS.

A number of other research analysts have also commented on the stock. BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Saturday. Jefferies Financial Group increased their price target on shares of DexCom to $148.00 and gave the stock a “buy” rating in a research report on Wednesday. Stephens increased their price target on shares of DexCom from $170.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday. Oppenheimer set a $150.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Wednesday. Finally, Raymond James increased their price target on shares of DexCom from $125.00 to $150.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 23rd. Seven analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. DexCom presently has a consensus rating of “Buy” and an average target price of $132.50.

Shares of DXCM opened at $149.46 on Thursday. The company has a quick ratio of 4.62, a current ratio of 4.71 and a debt-to-equity ratio of 0.60. DexCom has a 52 week low of $49.80 and a 52 week high of $152.14.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.29. The business had revenue of $266.70 million during the quarter, compared to analyst estimates of $242.72 million. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. The business’s quarterly revenue was up 44.5% compared to the same quarter last year.

In other news, CEO Kevin R. Sayer sold 11,161 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $123.22, for a total transaction of $1,375,258.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven Robert Pacelli sold 3,114 shares of the firm’s stock in a transaction that occurred on Tuesday, October 23rd. The stock was sold at an average price of $128.85, for a total transaction of $401,238.90. The disclosure for this sale can be found here. Insiders sold 157,892 shares of company stock valued at $21,864,030 in the last three months. Company insiders own 1.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of DXCM. Dimensional Fund Advisors LP increased its holdings in shares of DexCom by 16.7% during the first quarter. Dimensional Fund Advisors LP now owns 148,342 shares of the medical device company’s stock worth $11,001,000 after buying an additional 21,271 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of DexCom by 7.9% during the first quarter. Principal Financial Group Inc. now owns 33,469 shares of the medical device company’s stock worth $2,482,000 after buying an additional 2,459 shares in the last quarter. UBS Group AG increased its holdings in shares of DexCom by 76.3% during the first quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock worth $1,181,000 after buying an additional 6,890 shares in the last quarter. Clinton Group Inc. acquired a new stake in shares of DexCom during the second quarter worth approximately $201,000. Finally, State of Alaska Department of Revenue increased its holdings in shares of DexCom by 32.3% during the second quarter. State of Alaska Department of Revenue now owns 10,410 shares of the medical device company’s stock worth $988,000 after buying an additional 2,540 shares in the last quarter.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Balance Sheet

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.